Clinical Trial

Spinal Cord Stimulation for Refractory Pain in Erythromelalgia

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
Erythromelalgia is a rare disorder characterized by red, warm, and painful extremities, which is often precipitated by warm conditions. The pathophysiology is incompletely understood. The management of pain in erythromelalgia is challenging as no single therapy has been found to be effective. Response to pharmacotherapy varies, meaning that the physician has to take a stepwise trial and error approach with each patient. Consequently, this disorder is often associated with poorer health-related quality of life. There is currently no consensus or guideline on management of pain in erythromelalgia. Spinal cord stimulation is a widely applied therapy to treat severe chronic pain of various origin. Case reports and anecdotal evidence suggest that this therapy might alleviate refractory pain in patients with erythromelalgia. The aim of this trial is to evaluate the efficacy of spinal cord stimulation for refractory pain in erythromelalgia.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-07-30; most recent amendment 2025-07-07.
Status change: Not Yet Recruiting → Recruiting 2019-09-03
Trial Details
NCT Number NCT04039633
Lead Sponsor St. Olavs Hospital
Collaborators: Norwegian University of Science and Technology
Conditions Erythromelalgia
Enrollment 24 participants
Start Date 2019-08-26
Primary Completion 2026-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-08